Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus

Table 2 Meta regression for network meta-analyses

Intervention of studies	OR	95%CI	t	P value
Major adverse cardiovascular events
Comorbidities	1.02	0.96-1.09	0.78	0.45
HbA1c	0.92	0.81-1.03	-1.54	0.15
All-cause mortality
Comorbidities	1.08	0.97-1.21	1.57	0.14
HbA1c	1.03	0.92-1.15	0.59	0.57
Cardiovascular mortality
Comorbidities	1.05	0.96-1.15	1.24	0.23
HbA1c	1.01	0.86-1.18	0.08	0.93
Stroke
Comorbidities	1.00	0.90-1.12	-0.00	1.00
HbA1c	0.91	0.77-1.09	-1.12	0.28
Myocardial infarction
Comorbidities	1.00	0.91-1.08	-0.14	0.89
HbA1c	0.91	0.79-1.04	-1.51	0.16
Hospitalization for heart failure
Comorbidities	1.06	0.94-1.20	1.05	0.31
HbA1c	0.94	0.73-1.21	-0.50	0.62
Composite renal events
Comorbidities	1.12	0.98-1.28	1.80	0.10
HbA1c	0.98	0.79-1.22	-0.22	0.83
Serious adverse events
Comorbidities	1.02	0.97-1.07	0.80	0.43
HbA1c	0.97	0.88-1.06	-0.70	0.49
Diabetic ketoacidosis
Comorbidities	0.93	0.32-2.68	-0.15	0.88
HbA1c	0.70	0.11-4.28	-0.43	0.67
Pancreatitis
Comorbidities	0.94	0.67-1.33	-0.37	0.72
HbA1c	0.62	0.34-1.13	-1.71	0.11
Hypoglycemia
Comorbidities	1.48	0.60-3.67	0.93	0.37
HbA1c	0.76	0.30-1.92	-0.63	0.54
Acute kidney injury
Comorbidities	1.14	0.99-1.31	1.94	0.07
HbA1c	1.07	0.84-1.38	0.62	0.55

HbA1c: Hemoglobin a1c.